Highlights
- Daratumumab plus VTd (D-VTd) induction/consolidation and daratumumab maintenance consistently achieve the highest rates of minimal residual disease (MRD) negativity and progression-free survival (PFS) in newly diagnosed, transplant-eligible multiple myeloma.
- MRD negativity rates are improved at both 10-5 and 10-6 levels, regardless of cytogenetic risk or postinduction status, with daratumumab-based regimens.
- These benefits are maintained with a median follow-up of over 80 months, underscoring the long-term durability of deep responses.
- Daratumumab maintenance offers significant PFS advantages over observation, independent of prior induction/consolidation choice or MRD status post-consolidation.
Study Background and Disease Burden
Specialty calculators
For clinical reference; use professional judgment.
